BÖBREK NAKLİNDE HÜCRESEL TEDAVİLERİN KULLANIMI

Günümüzde, tıp, cerrahi alanında görülen gelişmeler ve teknolojik olarak geliştirilen modern ilaçların kulla nımıyla beraber, geçtiğimiz yüzyılda böbrek hastalık ları da dahil olmak üzere, ölümcül olan birçok hastalık artık tedavi edilebilir konuma gelmiştir. Böbrek nakli, elde edilen başarılar ile beraber, hem böbrek hasta lıkları için bir tedavi seçeneği haline gelmiş ve böb rek nakil oranları artış göstermiş, hem de beklenen yaşam süresi uzamıştır. Böbrek nakli yapılan hasta ların cerrahi sonrası tedavi süreçlerinde immünsüp resif ilaçlar kullanılmaktadır. Yeni geliştirilmeye çalışı lan tedavi seçenekleri ile hem böbrek naklinde elde edilen başarı oranı arttırılmaya çalışılmakta hem de immünsüpresif ilaçların kullanımının yol açtığı yan etkilerin giderilmesi amaçlanmaktadır. Hücresel te daviler de böbrek naklinde kullanılması için üzerinde çalışılan tedavi seçeneklerinden birisidir. Düzenleyici T hücreler, B hücreler ve makrofajlar; dendritik hüc reler ve mezenkimal kök hücreler organ nakillerinde kullanılması için araştırma ve deneme yapılan hücre kaynaklarındandır. Deney hayvanlarında organ nakil modellerinde yapılan çalışmalarda, hücre tedavileri ile başarılı sonuçlar alındığı gösterilmiştir. Bu derlemede, böbrek naklinde günümüzde kullanılan ve de kullanıl maya aday olan hücre tedavileri tartışılmıştır.

CELL THERAPIES IN KIDNEY TRANSPLANTATION

At the present time, with the development of medici ne, surgery and the use of technologically advanced modern drugs, many diseases, including kidney dise ases, have become treatable. Kidney transplantation has become a treatment option for kidney diseases and kidney transplant rates have increased as well as life expectancy has been prolonged by means of obtained success. Immunosuppressive drugs are used in the posttransplant treatment process of renal transplant patients. With the new treatment options, it is aimed to increase the success rate of kidney transplantation and also to eliminate the side effects which are caused by the use of immunosuppressive drugs. Cellular therapies are one of the treatment op tions that are studied for use in kidney transplantation. Regulator T cells, regulator B cells, regulator macrop hages, dendritic cells, mesenchymal stem cells are cell sources that are searched and experimented for use in organ transplantation. It has been shown that successful results have been obtained by using cell therapies in studies carried out with experimental ani mal models for transplantation. In this review, cell the rapies used in and candidate for renal transplantation are discussed.

PDF

___

1. Alikhan MA, Huynh M, Kitching AR, Ooi JD. Regulatory T cells in renal disease. Clin Transl Immunol 2018;7:1004-9.
2. Lamb KE, Lodhi S, Meier-Kriesche H-U. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450-62.
3. Stallone G, Infante B, Grandaliano G. Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J 2015;8:637-44.
4. Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation 2012;93:1–10.
5. Lechler RI, Lombardi G, Richard Batchelor J, Reinsmoen N, Bach FH. The molecular basis of alloreactivity. Immunol Today 1990;11:83-8.
6. Zhuang Q, Lakkis FG. Dendritic cells and innate immunity in kidney transplantation. Kidney Int 2015;87:712-18.
7. Matzinger P, Bevan MJ. Why do so many lymphocytes respond to major histocompatibility antigens? Cell Immunol 1977;29:1- 5.
8. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells D, Turka L. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001;166:973-81.
9. Liu Z, Fan H, Jiang S. CD4 + T-cell subsets in transplantation. Immunol Rev 2013;252:183-91.
10. Rosenberg AS, Mizuochi T, Sharrow SO, Singer A. Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection. J Exp Med 1987;165:1296- 315.
11. Jiang S, Herrera O, Lechler RI. New spectrum of allorecognition pathways: Implications for graft rejection and transplantation tolerance. Curr Opin Immunol 2004;16(5):550-7.
12. Lee CY, Lotfi-Emran S, Erdinc M, Murata K, Velidedeoglu E, Fox-Talbot K, et al. The involvement of fcr mechanisms in antibody-mediated rejection. Transplantation 2007;84:1324-34.
13. Williams MA, Bevan M. Effector and Memory CTL Differentiation. Annu Rev Immunol 2007;25:171-92.
14. Valujskikh A, Lakkis FG. In remembrance of things past: Memory T cells and transplant rejection. Immunol Rev 2003;196:65-74.
15. Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, Monteferrante G, et al. Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs. J Am Soc Nephrol 2007;18:1007-18.
16. Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005;5:465-74
17. Page AJ, Ford ML, Kirk AD. Memory T-cell-specific therapeutics in organ transplantation. Curr Opin Organ Transplant 2009;14:643-49.
18. Rudensky AY. Regulatory T Cells and Foxp3. Immunol Rev 2011;241:260-8.
19. Waldmann H, Hilbrands R, Howie D, Cobbold S: Harnessing FOXP3+ regulatory T cells for transplantation tolerance. J Clin Invest 2014;124:1439-45.
20. Marín E, Cuturi MC, Moreau A. Tolerogenic dendritic cells in solid organ transplantation: Where do we stand? Front Immunol 2018;9:274-6.
21. Chabannes D, Hill M, Merieau E, Rossignol J, Brion R, Soulillou JP, et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007;110(10):3691-4.
22. Franquesa M, Hoogduijn MJ, Reinders ME, Eggenhofer E, Engela AU, Mensah FK, et al. Mesenchymal stem cells in solid organ transplantation (MiSOT) fourth meeting: Lessons learned from first clinical trials. Transplantation 2013;96(3):234-8.
23. Riquelme P, Tomiuk S, Kammler A, Fändrich F, Schlitt HJ, Geissler EK, et al. IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther 2013;21(2):409-22.
24. Hill M, Thebault P, Segovia M, Louvet C, Bériou G, Tilly G, et al. Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through interferon-gamma and Epstein-Barr virus-induced gene 3. Am J Transplant 2011;11:2036-45.
25. Todo S, Yamashita K, Goto R, Zaitsu M, Nagatsu A, Oura T, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology 2016;64(2):632-43.
26. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973;137(5):1142-62.
27. Steinman R, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med. 1974;139(2):380-97.
28. Steinman RM, Lustig DS, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. 3 Functional properties in vivo. J Exp Med 1974;139(6):1431-45.
29. Steinman RM, Adams JC, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen. J Exp Med 1975;141(4):804- 20.
30. Steinman RM, Kaplan G, Witmer MD, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro. J Exp Med 1979;149(1):1-16.
31. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci 1995;92(17):8078-82.
32. Mellman I. Dendritic cells: master regulators of the immune response. Cancer Immunol Res 2013;1(3):145-49.
33. Bustos-Morán E, Blas-Rus N, Martín-Cófreces NB, Sánchez-Madrid F. Orchestrating Lymphocyte Polarity in Cognate Immune Cell–Cell Interactions Int Rev Cell Mol Biol 2016;327:195-261.
34. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol 2012;12(8):557-69.
35. Tisch R. Immunogenic versus tolerogenic denritic cells: A matter of maturation. Int Rev Immunol 2010;29(2):111-8.
36. Hubo M, Trinschek B, Kryczanowsky F, Tuettenberg A, Steinbrink K, Jonuleit H. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol 2013;4:82-7.
37. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194:769- 79.
38. Idoyaga J, Fiorese C, Zbytnuik L, Lubkin A, Miller J, Malissen B, et al. Specialized role of migratory dendritic cells in peripheral tolerance induction. J Clin Invest 2013;123(2):844-54.
39. Svajger U, Rozman P. Tolerogenic dendritic cells: molecular and cellular mechanisms in transplantation. J Leukoc Biol 2014;85(1):53-69.
40. Beriou G, Moreau A, Cuturi MC. Tolerogenic dendritic cells: Applications for solid organ transplantation. Curr Opin Organ Transplant 2012;17(1):42-7.
41. Yabu JM, Anderson MW, Kim D, Bradbury BD, Lou CD, Petersen J, et al. Sensitization from transfusion in patients awaiting primary kidney transplant. Nephrol Dial Transplant 2013;28(11):2908-18.
42. Alexander T, Sattler A, Templin L, Kohler S, Groß C, Meisel A, et al. Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis 2013;72(9):1549-58.
43. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299(5609):1057-61.
44. Raker VK, Domogalla MP, Steinbrink K. Tolerogenic dendritic cells for regulatory T cell induction in man. Front Immunol 201;6:569-72.
45. Allan SE, Broady R, Gregori S, Himmel ME, Locke N, Roncarolo MG, et al. CD4+ T-regulatory cells: Toward therapy for human diseases. Immunol Rev 2008;223:391-421.
46. Lam AJ, Hoeppli RE, Levings MK. Harnessing Advances in T Regulatory Cell Biology for Cellular Therapy in Transplantation. Transplantation 2017;101(10):2277-87.
47. Juvet SC, Whatcott AG, Bushell AR, Wood KJ. Harnessing regulatory t cells for clinical use in transplantation: The end of the beginning. Am J Transplant 2014;14(4):750-63.
48. Hoeppli RE, Macdonald KG, Levings MK, Cook L. How antigen specificity directs regulatory T-cell function: Self, foreign and engineered specificity. HLA 2016;88(1-2):3-13.
49. Duggleby R, Danby RD, Madrigal JA, Saudemont A. Clinical grade regulatory CD4+T cells (Tregs): Moving toward cellular-based immunomodulatory therapies. Front Immunol 2018;9:252-56.
50. Sicard A, Boardman DA, Levings MK. Taking regulatory T-cell therapy one step further. Curr Opin Organ Transplant 2018;23:509-15.
51. Dons EM, Raimondi G, Cooper DKC, Thomson AW. Non-Human Primate Regulatory T Cells: Current Biology and Implications for Transplantation. Transplantation 2010; 90(8):811-16.
52. Pilar F, Lourdes V, Dolores C, Pedro G-C, Lucia L, Jesus SM. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant. Eur J Haematol 2013; 91(2):129-34.
53. Trzonkowski P, Bieniaszewska M, Juścińska J, Dobyszuk A, Krzystyniak A, Marek N. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol 2009; 133(1):22-6.
54. Tang Q, Lee K. Regulatory T-cell therapy for transplantation: How many cells do we need? Curr Opin Organ Transplant 2012;17(4):349-54.
55. Bocian K, Kiernozek E, Domagała-Kulawik J, Korczak-Kowalska G, Stelmaszczyk-Emmel A, Drela N. Expanding Diversity and Common Goal of Regulatory T and B Cells. I: Origin, Phenotype, Mechanisms. Archivum Immunologiae et Therapiae Experimentalis 2017;65(6):501-20.
56. Natarajan P, Singh A, McNamara JT, Secor ER, Guernsey LA, Thrall RS. Regulatory B cells from hilar lymph nodes of tolerant mice in a murine model of allergic airway disease are CD5+, express TGF-β, and co-localize with CD4+Foxp3+T cells. Mucosal Immunol 2012; 5(6):691-701.
57. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3(10):944-50.
58. Durand J CE. B cells with regulatory properties in transplantation tolerance. World J Transplant 2015;21:425-36.
59. Mauri C, Bosma A. Immune Regulatory Function of B Cells. Annu Rev Immunol 2012; 30:221-41.
60. Parker DC, Greiner DL, Phillips NE, Appel MC, Steele AW, Durie FH. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci 1995; 92(21):9560-64.
61. Niimi M, Pearson TC, Larsen CP, Alexander DZ, Hollenbaugh D, Aruffo A. The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo. J Immunol 1998; 161(10):5331-37.
62. Shabir S, Girdlestone J, Briggs D, Kaul B, Smith H, Daga S. Transitional B lymphocytes are associated with protection from kidney allograft rejection: A prospective study. Am J Transplant 2015; 15(5):1384-91.
63. Sun Q, Huang Z, Han F, Zhao M, Cao R, Zhao D. Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: Pilot results of a multicenter randomized controlled trial. J Transl Med 2018; 16(1):52-6.
64. English K, French A, Wood KJ. Mesenchymal stromal cells: Facilitators of successful transplantation? Cell Stem Cell 2010;7(4):431-42.
65. English K, Mahon BP. Allogeneic mesenchymal stem cells: Agents of immune modulation. Journal of Cellular Biochemistry 2011;112(8):1963-68.
66. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4):315-7.
67. Bianco P. “Mesenchymal” Stem Cells. Annu Rev Cell Dev Biol 2014; 30:677-704.
68. Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L. Immunological characterization of multipotent mesenchymal stromal cells-The international society for cellular therapy (ISCT) working proposal. Cytotherapy 2013; 15(9):1054-61.
69. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI. Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric Oxide. Cell Stem Cell 2008; 2(2):141-50.
70. Ren G, Su J, Zhang L, Zhao X, Ling W, L’Huillie A. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009; 27(8):1954-62.
71. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001;2(10):907-16.
72. Mellor AL, Munn DH. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4(10):762-74.
73. Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology of mesenchymal stem cells. Cell Death Differ 2014;21(2):216-25.
74. Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012; 307(11):1169-77.
75. Reinders MEJ, Fijter JW De, Roelofs H, Bajema IM, Vries DK De, Schaapherder AF. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med 2013; 2(2):107-11.
76. Crop M, Baan C, Weimar W, Hoogduijn M. Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transpl Int 2009; 22(4):365-76.
77. Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: A clinical pilot study. Transplantation 2013; 95(1):161-8.
78. Coulson-Thomas VJ, Coulson-Thomas YM, Gesteira TF, Kao WW-Y. Extrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells Suppress the Immune System. Ocul Surf 2016; 14(2):121-34.
79. Sivanathan KN, Gronthos S, Rojas-Canales D, Thierry B, Coates PT. Interferon-Gamma Modification of Mesenchymal Stem Cells: Implications of Autologous and Allogeneic Mesenchymal Stem Cell Therapy in Allotransplantation. Stem Cell Rev Reports 2014; 10(3):351-75.
80. Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA. Autologous Mesenchymal Stromal Cells and Kidney Transplantation: A Pilot Study of Safety and Clinical Feasibility. Clin J Am Soc Nephrol 2011;6(2):412-22.
81. Casiraghi F, Perico N, Cortinovis M, Remuzzi G. Mesenchymal stromal cells in renal transplantation: Opportunities and challenges. Nat Rev Nephrol 2016; 12(4):241-53.
82. Sheng H, Wang Y, Jin Y, Zhang Q, Zhang Y, Wang L. A critical role of IFNγ in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 2008; 18(8):846-.57
83. Duijvestein M, Wildenberg ME, Welling MM, Hennink S, Molendijk I, Van Zuylen VL. Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 2011; 29(10):1549-58.
84. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101(9):3722-29.
85. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-Like Activity of Mesenchymal Stem Cells: Functional Discrimination Between Cellular Responses to Alloantigens and Recall Antigens. J Immunol 2003; 171(7):3426-34.
86. Rafei M, Birman E, Forner K, Galipeau J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther 2009; 17(10):1799-803.
87. Schu S, Nosov M, O’Flynn L, Shaw G, Treacy O, et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012; 16(9):2094-103.
88. Badillo AT, Beggs KJ, Javazon EH, Tebbets JC, Flake AW. Murine Bone Marrow Stromal Progenitor Cells Elicit an In Vivo Cellular and Humoral Alloimmune Response. Biol Blood Marrow Transplant 2007; 13(4):412-22.